While the expression of CXCR5 on TFH did not change in fingolimod-treated MS patients (figure 4B; table S2), a significant increase of the expression of PD-1 on PB TFH cells was observed during follow-up (p<0.05; figure 4C; table S2). This evidence concerns the gene CXCR5 and myeloid sarcoma.